Novo Nordisk Wins FDA Panel Recommendation for Once-Weekly Diabetes Candidate Semaglutide

Novo Nordisk is on track to win FDA approval later this year to market the first once-weekly type 2 diabetes treatment following an advisory committee’s unanimous recommendation yesterday in favor of the company’s semaglutide.The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 16 to 0, with one abstention, to recommend approval of Novo Nordisk’s semaglutide, concluding that the glycemic control injection treatment was safe and effective.The FDA u